Actualités Oncocyte Corporation - OCX | Actions NASDAQ

Votre Hub pour des idées et discussions en direct en temps réel

Oncocyte To Announce First Quarter 2023 Financial Results

IRVINE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☒ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Amended Statement of Changes in Beneficial Ownership (4/a)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Oncocyte Presents New Data at AACR

IRVINE, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision...

Amended Statement of Ownership (sc 13g/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED...

Annual Report (10-k)

0001642380 false FY

Oncocyte Announces Reduction in Force

IRVINE, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Amended Statement of Beneficial Ownership (sc 13d/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF...

Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer

IRVINE, Calif., April 07, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostic...

Current Report Filing (8-k)

0001642380 false 0001642380 2023-04-03 2023-04-03 iso4217:USD xbrli:shares...

Oncocyte Pricing of $13.86 Million Public Offering of Common Stock

IRVINE, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), (“Oncocyte” or the...

Notification That Annual Report Will Be Submitted Late (nt 10-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...

Current Report Filing (8-k)

0001642380 false 0001642380 2023-03-31 2023-03-31 iso4217:USD xbrli:shares...

Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K

IRVINE, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Oncocyte Corporation (OCX)

Votre Hub pour des idées et discussions en direct en temps réel

OCX Actualités

Oncocyte To Announce First Quarter 2023 Financial Results

Statement of Changes in Beneficial Ownership (4)

Amended Statement of Changes in Beneficial Ownership (4/a)

Oncocyte Presents New Data at AACR

Amended Statement of Ownership (sc 13g/a)

Annual Report (10-k)

Oncocyte Announces Reduction in Force

Statement of Changes in Beneficial Ownership (4)

Amended Statement of Beneficial Ownership (sc 13d/a)

Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer

Current Report Filing (8-k)

Oncocyte Pricing of $13.86 Million Public Offering of Common Stock

Notification That Annual Report Will Be Submitted Late (nt 10-k)

Current Report Filing (8-k)

Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Oncocyte Corporation (OCX) Actualités

Oncocyte Corporation (OCX)

Votre Hub pour des idées et discussions en direct en temps réel

OCX Actualités

Oncocyte To Announce First Quarter 2023 Financial Results

Statement of Changes in Beneficial Ownership (4)

Amended Statement of Changes in Beneficial Ownership (4/a)

Oncocyte Presents New Data at AACR

Amended Statement of Ownership (sc 13g/a)

Annual Report (10-k)

Oncocyte Announces Reduction in Force

Statement of Changes in Beneficial Ownership (4)

Amended Statement of Beneficial Ownership (sc 13d/a)

Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer

Current Report Filing (8-k)

Oncocyte Pricing of $13.86 Million Public Offering of Common Stock

Notification That Annual Report Will Be Submitted Late (nt 10-k)

Current Report Filing (8-k)

Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités